Inflammation is characterized by redness, heat, swelling, pain and sometimes loss of function of tissues. Cyclooxygenases (COXs) are mainly responsible for inflammation. Constitutive COX-1 is responsible for providing cytoprotection in gastrointestinal (GI) tract whereas inducible COX-2 facilitates inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat the signs and symptoms of inflammation. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as Aspirin, Diclofenac, Flurbiprofen and Ibuprofen act via the inhibition of the COX-1 isoenzyme or the combined inhibition of COX-1 and COX-2 isoenzymes. However they show greater selectivity for COX-1 than COX-2 as well as produce serious side effect like hepatic toxicity. Therefore, it is urgently required to identify new targets that are essential for the design and development of novel anti-inflammatory agents as an alternative to NSAIDs. The relevant information provided in this manuscript can be found useful for drug design of novel anti-inflammatory agents having greater safety, selectivity and potency as well as lesser side effects.
| Autorius: | Rajeev Kharb |
| Leidėjas: | LAP LAMBERT Academic Publishing |
| Išleidimo metai: | 2018 |
| Knygos puslapių skaičius: | 88 |
| ISBN-10: | 6139900891 |
| ISBN-13: | 9786139900893 |
| Formatas: | 220 x 150 x 6 mm. Knyga minkštu viršeliu |
| Kalba: | Anglų |
Parašykite atsiliepimą apie „Exploring Privileged Heterocyclic Scaffolds:: Their Scope as Novel Anti-Inflammatory Drug Candidates“
